Meeting
2021 ASCO Annual Meeting
Changes in patient-reported outcomes (PROs) and tumor markers (TMs) to predict treatment response and survival outcomes in patients with metastatic gastrointestinal (GI) cancer.
Authors
Joy X. Jarnagin
Massachusetts General Hospital, Boston, MA
Joy X. Jarnagin , Aparna Raj Parikh , Emily E. Van Seventer , Yojan Shah , Islam Baiev , Amirkasra Mojtahed , Jill N. Allen , Lawrence Scott Blaszkowsky , Jeffrey William Clark , Joseph Wang Franses , Bruce J. Giantonio , Lipika Goyal , Samuel J Klempner , Eric Roeland , David P. Ryan , Colin D. Weekes , Giulia Siravegna , Nora K. Horick , Ryan Bruce Corcoran , Ryan David Nipp
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality Improvement
Track
Quality Care/Health Services Research
Sub Track
Outcomes
Clinical Trial Registration Number
18-380
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 6560)
DOI
10.1200/JCO.2021.39.15_suppl.6560
Abstract #
6560
Poster Bd #
Online Only
Abstract Disclosures
Funded by Conquer Cancer
Similar Posters
Poster
2022 ASCO Annual Meeting
Changes in Functional Assessment of Cancer Therapy: General (FACT-G) to predict treatment response and survival outcomes in patients with metastatic gastrointestinal (GI) cancer.
First Author: Joy X. Jarnagin
Poster
2020 ASCO Virtual Scientific Program
Quality of life, vascular endothelial growth factor inhibition, and survival outcomes with combination oral metronomic therapy in platinum refractory epithelial ovarian carcinoma: Results from a randomized study.
First Author: Aparna Sharma
Poster
2024 ASCO Genitourinary Cancers Symposium
A meta-analysis of overall survival and response in metastatic adrenocortical carcinoma: A review of 23 prospective trials of 880 patients.
First Author: Angus Hall
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Kinetics of CA19-9 decline in a randomized phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracial/leucovorin (NALIRIFOX) or nab-paclitaxel plus gemcitabine (GEM+NABP) in patients who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas (NAPOLI 3).
First Author: Sreenivasa R Chandana